Economic burden of central nervous system metastases in human epidermal growth factor receptor 2-positive breast cancer.
Naomi R M SchwartzKendra DeBuskAndres Forero-TorresJoseph FelicianoVamshi Ruthwik AnupindiJason YeawAli McBridePublished in: Future oncology (London, England) (2021)
Aim: Compare healthcare resource utilization and costs among patients with HER2+ metastatic breast cancer (MBC) with and without central nervous system (CNS) metastases. Methods: Retrospective matched cohort study using IQVIA's PharMetrics® Plus claims database. Results: Patients with CNS metastases (n = 753) experienced more outpatient, emergency room and inpatient visits versus controls (n = 753; all p < 0.05). In the post-index year, median total all-cause healthcare costs were significantly higher among patients with CNS metastases versus controls ($112,402 vs $50,835; p < 0.0001); outpatient costs primarily drove the cost differential. Conclusion: More effective therapies are needed that improve clinical outcomes and reduce economic burden associated with CNS metastases in patients with HER2+ MBC.
Keyphrases
- healthcare
- epidermal growth factor receptor
- blood brain barrier
- positive breast cancer
- metastatic breast cancer
- emergency department
- endothelial cells
- tyrosine kinase
- public health
- advanced non small cell lung cancer
- mental health
- health insurance
- induced pluripotent stem cells
- social media
- pluripotent stem cells